- Conditions
- Chronic Kidney Disease, Chronic Renal Failure
- Interventions
- Epoetin Hospira, Epogen (Amgen)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 84
- States / cities
- Montgomery, Alabama • Tempe, Arizona • Alhambra, California + 65 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Kidney Disease
- Interventions
- Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 44
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
- Conditions
- Chronic Kidney Failure
- Interventions
- Not listed
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Easton, Maryland • Arlington, Virginia
- Conditions
- Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
- Interventions
- Renal Autologous Cell Therapy (REACT)
- Biological
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Chronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal Failure, Disordered Mineral Metabolism, End Stage Renal Disease, Hyperparathyroidism, Hypophosphatemia, Kidney Disease, Kidney Transplantation, Post Renal Transplantation
- Interventions
- Cinacalcet, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Self-management of BP medications, Self-monitoring of home BP
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Kidney Disease
- Interventions
- Calcium acetate oral solution (COS), Sevelamer carbonate
- Drug
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • North Haven, Connecticut • New York, New York
- Conditions
- Kidney Disease, Kidney Failure, Kidney Failure, Chronic, Healthy Volunteers, Renal Tubular Toxicity
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 3 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- End Stage Renal Disease
- Interventions
- Xeltis Hemodialysis Access (aXess) graft
- Device
- Lead sponsor
- Xeltis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
- Conditions
- Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Alessandro Doria
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more
- Conditions
- Coronary Artery Disease, Diabetes Mellitus
- Interventions
- ticagrelor
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Chronic Kidney Disease, Hypertension
- Interventions
- Protocolized, pharmacist-delivered CKD Action Plan
- Other
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Chronic Kidney Disease
- Interventions
- Placebo, AST-120
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Alhambra, California + 38 more
- Conditions
- Genetic Predisposition, Chronic Kidney Diseases, Nephropathy, APOL1 Associated Kidney Disease, Disparities
- Interventions
- Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
- Genetic
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Kidney Diseases
- Interventions
- Active taVNS, Sham taVNS
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- End Stage Renal Disease
- Interventions
- Erythropoietin, Pentoxifylline
- Drug
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
- Conditions
- Kidney Diseases, End Stage Renal Disease
- Interventions
- telavancin
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
- Conditions
- End Stage Renal Disease
- Interventions
- CMVIG
- Drug
- Lead sponsor
- Tampa General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- End Stage Renal Disease, Kidney Failure
- Interventions
- Provider educational materials, Patient letters
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio
- Conditions
- Improve Endothelial Function and Decrease Vascular Stenosis
- Interventions
- Sildenafil, Placebo
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Physical Activity, End Stage Kidney Disease, Hemodialysis
- Interventions
- Fitbit
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Cardiovascular Disease, Chronic Kidney Disease
- Interventions
- angiotensin converting enzyme inhibitor, lisinopril
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- End-stage Renal Disease
- Interventions
- ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- AZD1722, Placebo
- Drug
- Lead sponsor
- Ardelyx
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Denver, Colorado